“Severe coronavirus disease 2019 (COVID-19) is associated with dysregulated inflammation”.
Baricilinib is an oral anti-inflammatory drug previously used in rheumatoid arthritis. It is a janus kinase inhibitor (a family of intracellular, non-receptor tyrosine kinases involved in cell growth, survival, development and differentiation which are critically important in blocking immune cells from overproducing cytokines -small proteins involved in immune and inflammatory responses). The WHO recommends it be given with corticosteroids for severe or critical COVID-19.
Sotrovimab is a synthetic monoclonal antibody similar in function to one of the body’s natural antibodies and which is “designed to restore, mimic, inhibit or enhance immune system functions”. It is now conditionally recommended for treating mild/moderate COVID-19 in patients at high risk for hospitalization.
This “eighth update” of the WHO living guidelines on therapeutics and COVID-19 utilizes evidence from 7 trials involving over 4,000 patients with non-severe, severe and critical COVID-19.